|
1.
|
Cornelio DB, Roesler R and Schwartsmann G:
Gastrin-releasing peptide receptor as a molecular target in
experimental anticancer therapy. Ann Oncol. 18:1457–1466. 2007.
|
|
2.
|
Patel O, Shulkes A and Baldwin GS:
Gastrin-releasing peptide and cancer. Biochim Biophys Acta.
1766:23–41. 2006.
|
|
3.
|
Cornelio DB, Meurer L, Roesler R and
Schwartsmann G: Gastrin-releasing peptide receptor expression in
cervical cancer. Oncology. 73:340–345. 2007.
|
|
4.
|
Cornelio DB, Meurer L, Schwartsmann G and
Roesler R: The gastrin-releasing peptide receptor as a marker of
dysplastic alterations in cervical epithelial cells. Oncology.
82:90–97. 2012.
|
|
5.
|
Giacchetti S, Gauvillé C, de Crémoux P, et
al: Characterization, in some human breast cancer cell lines, of
gastrin-releasing peptide-like receptors which are absent in normal
breast epithelial cells. Int J Cancer. 46:293–298. 1990.
|
|
6.
|
Gugger M and Reubi JC: Gastrin-releasing
peptide receptors in non-neoplastic and neoplastic human breast. Am
J Pathol. 155:2067–2076. 1999.
|
|
7.
|
Halmos G, Wittliff JL and Schally AV:
Characterization of bombesin/gastrin-releasing peptide receptors in
human breast cancer and their relationship to steroid receptor
expression. Cancer Res. 55:280–287. 1995.
|
|
8.
|
Sun B, Schally AV and Halmos G: The
presence of receptors for bombesin/GRP and mRNA for three receptor
subtypes in human ovarian epithelial cancers. Regul Pept. 90:77–84.
2000.
|
|
9.
|
Chatzistamou I, Schally AV, Szepeshazi K,
et al: Inhibition of growth of ES-2 human ovarian cancers by
bombesin antagonist RC-3095, and luteinizing hormone-releasing
hormone antagonist Cetrorelix. Cancer Lett. 171:37–45. 2001.
|
|
10.
|
Miyazaki M, Lamharzi N, Schally AV, et al:
Inhibition of growth of MDA-MB-231 human breast cancer xenografts
in nude mice by bombesin/gastrin-releasing peptide (GRP)
antagonists RC-3940-II and RC-3095. Eur J Cancer. 34:710–717.
1998.
|
|
11.
|
Yano T, Pinski J, Szepeshazi K, et al:
Inhibitory effect of bombesin/gastrin-releasing peptide antagonist
RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75
on the growth of MCF-7 MIII human breast cancer xenografts in
athymic nude mice. Cancer. 73:1229–1238. 1994.
|
|
12.
|
Huang EJ and Reichardt LF: Trk receptors:
roles in neuronal signal transduction. Annu Rev Biochem.
72:609–642. 2003.
|
|
13.
|
Desmet CJ and Peeper DS: The neurotrophic
receptor TrkB: a drug target in anti-cancer therapy? Cell Mol Life
Sci. 63:755–759. 2006.
|
|
14.
|
Roesler R, de Farias CB, Abujamra AL,
Brunetto AL and Schwartsmann G: BDNF/TrkB signaling as an
anti-tumor target. Expert Rev Anticancer Ther. 11:1473–1475.
2011.
|
|
15.
|
Thiele CJ, Li Z and McKee AE: On Trk - the
TrkB signal transduction pathway is an increasingly important
target in cancer biology. Clin Cancer Res. 15:5962–5967. 2009.
|
|
16.
|
Akil H, Perraud A, Mélin C, Jauberteau MO
and Mathonnet M: Fine-tuning roles of endogenous brain-derived
neurotrophic factor, TrkB and sortilin in colorectal cancer cell
survival. PLoS One. 6:e250972011.
|
|
17.
|
de Farias CB, Rosemberg DB, Heinen TE, et
al: BDNF/TrkB content and interaction with gastrin-releasing
peptide receptor blockade in colorectal cancer. Oncology.
79:430–439. 2010.
|
|
18.
|
Li Z, Oh DY, Nakamura K and Thiele CJ:
Perifosine-induced inhibition of Akt attenuates brain-derived
neurotrophic factor/TrkB-induced chemoresistance in neuroblastoma
in vivo. Cancer. 117:5412–5422. 2011.
|
|
19.
|
Perez-Pinera P, Hernandez T, García-Suárez
O, et al: The Trk tyrosine kinase inhibitor K252α regulates growth
of lung adenocarcinomas. Mol Cell Biochem. 295:19–26. 2007.
|
|
20.
|
Au CW, Siu MK, Liao X, et al: Tyrosine
kinase B receptor and BDNF expression in ovarian cancers - effect
on cell migration, angiogenesis and clinical outcome. Cancer Lett.
281:151–161. 2009.
|
|
21.
|
Moon A, Won KY, Lee JY, et al: Expression
of BDNF, TrkB, and p53 in early-stage squamous cell carcinoma of
the uterine cervix. Pathology. 43:453–458. 2011.
|
|
22.
|
Qiu L, Zhou C, Sun Y, et al: Crosstalk
between EGFR and TrkB enhances ovarian cancer cell
migration and proliferation. Int J Oncol. 29:1003–1011. 2006.
|
|
23.
|
Yu X, Liu L, Cai B, He Y and Wan X:
Suppression of anoikis by the neurotrophic receptor TrkB in human
ovarian cancer. Cancer Sci. 99:543–552. 2008.
|
|
24.
|
Patani N, Jiang WG and Mokbel K:
Brain-derived neurotrophic factor expression predicts adverse
pathological and clinical outcomes in human breast cancer. Cancer
Cell Int. 11:232011.
|
|
25.
|
Vanhecke E, Adriaenssens E, Verbeke S, et
al: Brain-derived neurotrophic factor and neurotrophin-4/5 are
expressed in breast cancer and can be targeted to inhibit tumor
cell survival. Clin Cancer Res. 17:1741–1752. 2011.
|
|
26.
|
de Farias CB, Lima RC, Lima LO, et al:
Stimulation of proliferation of U138-MG glioblastoma cells by
gastrin-releasing peptide in combination with agents that enhance
cAMP signaling. Oncology. 75:27–31. 2008.
|
|
27.
|
Flores DG, de Farias CB, Leites J, et al:
Gastrin-releasing peptide receptors regulate proliferation of C6
Glioma cells through a phosphatidylinositol 3-kinase-dependent
mechanism. Curr Neurovasc Res. 5:99–105. 2008.
|
|
28.
|
Yano T, Pinski J, Groot K and Schally AV:
Stimulation by bombesin and inhibition by
bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of
human breast cancer cell lines. Cancer Res. 52:4545–4547. 1992.
|
|
29.
|
Patel KV and Schrey MP: Activation of
inositol phospholipid signaling and Ca2+ efflux in human
breast cancer cells by bombesin. Cancer Res. 50:235–239. 1990.
|
|
30.
|
Abujamra AL, Almeida VR, Brunetto AL,
Schwartsmann G and Roesler R: A gastrin-releasing peptide receptor
antagonist stimulates Neuro2α neuroblastoma cell growth: prevention
by a histone deacetylase inhibitor. Cell Biol Int. 33:899–903.
2009.
|
|
31.
|
Pinski J, Schally AV, Halmos G, et al:
Somatostatin analogues and bombesin/gastrin-releasing peptide
antagonist RC-3095 inhibit the growth of human glioblastomas in
vitro and in vivo. Cancer Res. 54:5895–5901. 1994.
|
|
32.
|
Czepielewski RS, Porto BN, Rizzo LB, et
al: Gastrin-releasing peptide receptor (GRPR) mediates chemotaxis
in neutrophils. Proc Natl Acad Sci USA. 109:547–552. 2012.
|
|
33.
|
Roesler R, Luft T, Oliveira SH, et al:
Molecular mechanisms mediating gastrin-releasing peptide receptor
modulation of memory consolidation in the hippocampus.
Neuropharmacology. 51:350–357. 2006.
|
|
34.
|
Roesler R, Meller CA, Kopschina MI, et al:
Intrahippocampal infusion of the bombesin/gastrin-releasing peptide
antagonist RC-3095 impairs inhibitory avoidance retention.
Peptides. 24:1069–1074. 2003.
|
|
35.
|
Jensen RT, Battey JF, Spindel ER and Benya
RV: International Union of Pharmacology. LXVIII. Mammalian bombesin
receptors: nomenclature, distribution, pharmacology, signaling, and
functions in normal and disease states. Pharmacol Rev. 60:1–42.
2008.
|
|
36.
|
Chao C, Ives K, Hellmich HL, Townsend CM
Jr and Hellmich MR: Gastrin-releasing peptide receptor in breast
cancer mediates cellular migration and interleukin-8 expression. J
Surg Res. 156:26–31. 2009.
|
|
37.
|
Bajo AM, Schally AV, Krupa M, et al:
Bombesin antagonists inhibit growth of MDA-MB-435
estrogen-independent breast cancers and decrease the expression of
the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes. Proc
Natl Acad Sci USA. 99:3836–3841. 2002.
|
|
38.
|
Chatzistamou I, Schally AV, Sun B, Armatis
P and Szepeshazi K: Inhibition of growth of OV-1063 human
epithelial ovarian cancers and c-jun and c-fos oncogene expression
by bombesin antagonists. Br J Cancer. 83:906–913. 2000.
|
